OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Advani Discusses Outcomes in ALCL

March 11th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses outcomes for patients with anaplastic large-cell lymphoma.

Dr. Ron Bose on HER2 Gene Mutations in Breast Cancer

March 8th 2013

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.

Dr. Antonarakis on Sequencing ADT and Sipuleucel-T

March 7th 2013

Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.

Dr. Grady on Gene Profiling of CTCs in Pancreatic Cancer

March 7th 2013

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from an ongoing prospective study looking at gene expression profiling of circulating tumor cells in patients with unresectable pancreatic cancer.

Dr. Zelenetz on Treating Hematologic Malignancies

March 6th 2013

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

Dr. Kandalaft on an Ovarian Cancer Immunotherapy

March 5th 2013

Lana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Dr. Robert Motzer Reviews the Phase III COMPARZ Study

March 5th 2013

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.

Dr. Ari Melnick on MALT1 as a Potential Target in DLBCL

March 5th 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses MALT1 as a potential target for patients with activated B cell-like diffuse large B-cell lymphoma.

Dr. Richard Finn on the Rationale for Targeting CDK4/6

March 4th 2013

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

Dr. Bendell on Hsp90 Inhibition in Advanced Solid Tumors

March 4th 2013

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Dr. Vogelzang on Sequencing Abiraterone and Enzalutamide

March 1st 2013

Nicholas J. Vogelzang, MD, from Comprehensive Cancer Centers of Nevada, discusses sequencing abiraterone acetate and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer.

Dr. Richard T. Silver Discusses the Use of Interferons in MPNs

March 1st 2013

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms.

Justin Balko on JAK2 Amplification in TNBC

February 28th 2013

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.

Dr. Mesa on the Role of JAK2 Inhibitors in Myelofibrosis

February 28th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelofibrosis.

Dr. Gomella on the Value of a Multidisciplinary Cancer Center

February 27th 2013

Leonard G. Gomella, MD, discusses the benefits of the multidisciplinary center at Jefferson Kimmel Cancer Center.

Dr. Yao on Octreotide in Elderly Patients with NET

February 27th 2013

James C. Yao, MD, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the analysis of the linked SEER-Medicare database in patients with neuroendocrine tumors.

Dr. William Oh Discusses Dasatinib in Metastatic CRPC

February 27th 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses findings from the READY trial that added dasatinib to docetaxel as a treatment for men with metastatic castration-resistant prostate cancer.

Dr. Vahdat on Frontline Eribulin Plus Trastuzumab in MBC

February 26th 2013

Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.

Dr. Kamat on a Molecular Definition of BCG Failure

February 26th 2013

Ashish M. Kamat, MD, from MD Anderson Cancer Center, discusses enhancing clinical trial recruitment through a novel definition of BCG therapy failure in patients with nonmuscle invasive bladder cancer.

Dr. Antonarakis Describes the TAXYNERGY Trial in mCRPC

February 25th 2013

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.